The Alliance for Clinical Trials in Oncology (Alliance), one of five National Clinical Trials Network groups, serves as the parent organization for the Alliance NCI Community Oncology Research Program (NCORP) Research Base (Alliance NCORP). The Alliance NCORP conducts interventional and observational clinical and translational research as well as database studies ? all of which address important questions relevant to cancer prevention, symptom control, and cancer care delivery. In addition, the Alliance NCORP conducts clinically important quality of life studies that are embedded within cancer treatment trials. It places special emphasis on minority, underserved and older patients at risk for or diagnosed with cancer, and on building strong collegial relationships with NCORP Community sites and Minority/Underserved Community sites. The Alliance NCORP committee membership includes rich representation from both community-based and academic medical centers, as well as patient advocates, thus generating research results relevant to cancer patients across the United States. The Alliance NCORP also emphasizes mentorship and training of junior investigators. Over this past grant cycle, i.e., since August 2014, the Alliance NCORP has published 148 manuscripts and abstracts. This work has included practice-changing research in such areas as the prevention of chemotherapy-induced nausea and vomiting, the prevention of skeletal-related events from osseous metastases, the management of brain metastases, and the integration of patient-reported outcomes into cancer clinical trials. The Alliance NCORP conducts translational research that requires the collection of tumor tissue, premalignant tissue samples, blood, and other human biospecimens; and shares data and biospecimens for pooled analyses and other scientific collaborations. These biospecimens create an invaluable repository for understanding clinical observations from a mechanistic standpoint. The Alliance NCORP also collaborates broadly with other NCI-funded investigators and consortia, as well as with investigators supported through non-NCI sources. This practice-changing research and the scientific questions answered by the Alliance NCORP provide meaningful and innovative contributions to clinical and translational oncology, which can be conducted only within a publicly-funded research network.

Public Health Relevance

Alliance NCORP Research Base Project Narrative The Alliance NCI Community Oncology Research Program (NCORP) Research Base conducts research in cancer prevention, cancer symptom control, and cancer care delivery with a special emphasis on minority, underserved, and older patients and with a strong commitment to building collegial relationships with NCORP Community sites and Minority/Underserved Community sites. The Alliance NCORP seeks to continue its mission into the next grant cycle of generating practice-changing research that directly and favorably impacts the lives of cancer patients and those at risk for cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
7UG1CA189823-07
Application #
10172168
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
St Germain, Diane
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2020-08-21
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Alliance Nctn Foundation
Department
Type
DUNS #
117404554
City
Chicago
State
IL
Country
United States
Zip Code
60606
Gajra, Ajeet; McCall, Linda; Muss, Hyman B et al. (2018) The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). J Geriatr Oncol 9:221-227
Sio, Terence T; Atherton, Pamela J; Pederson, Levi D et al. (2018) Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. Int J Radiat Oncol Biol Phys :
Tallarico, Michael; Foster, Jared C; Seisler, Drew et al. (2018) Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). J Geriatr Oncol 9:321-328
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506
Pacyna, Joel E; Kim, Simon; Yost, Kathleen et al. (2018) The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD. BMC Cancer 18:788
Morrison, Vicki A; McCall, Linda; Muss, Hyman B et al. (2018) The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol 9:228-234
Freedman, Rachel A; Dockter, Travis J; Lafky, Jacqueline M et al. (2018) Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602). Oncologist 23:1016-1023
Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334

Showing the most recent 10 out of 101 publications